Obesity, adipokines, and prostate cancer in a prospective population-based study

Jacques Baillargeon, Elizabeth A. Platz, David P. Rose, Brad H. Pollock, Donna Pauler Ankerst, Steven Haffner, Betsy Higgins, Anna Lokshin, Dean Troyer, Javier Hernandez, Steve Lynch, Robin J. Leach, Ian M. Thompson

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Background: The purpose of this investigation was to examine the association of obesity and the adipokines leptin, adiponectin, and interleukin-6 (IL-6) with prostate cancer risk and aggressiveness. Methods: One hundred twenty-five incident prostate cancer cases and 125 age-matched controls were sampled from among participants in the original San Antonio Center for Biomarkers of Risk of Prostate Cancer cohort study. The odds ratios (OR) of prostate cancer and high-grade disease (Gleason sum >7) associated with the WHO categories of body mass index (kg/m2) and with tertiles of serum concentrations of adiponectin, leptin, and IL-6 were estimated using multivariable conditional logistic regression models. Results: Body mass index was not associated with either incident prostate cancer [obese versus normal; OR, 0.75; 95% confidence interval (95% CI), 0.38-1.48; Ptrend = 0.27] or high-grade versus low-grade disease (OR, 1.17; 95% CI, 0.39-3.52; P trend = 0.62). Moreover, none of the three adipokines was statistically significant associated with prostate cancer risk or high-grade disease, respectively: leptin (highest versus lowest tertile; OR, 0.77; 95% CI, 0.28-1.37; Ptrend = 0.57; OR, 1.20; 95% CI, 0.48-3.01; P trend = 0.85); adiponectin (OR, 0.87; 95% CI, 0.46-1.65; P trend = 0.24; OR, 1.93; 95% CI, 0.74-5.10; Ptrend = 0.85); IL-6 (OR, 0.84; 95% CI, 0.46-1.53; Ptrend = 0.98; OR, 0.84; 95% CI, 0.30-2.33; Ptrend = 0.17). Conclusions: Findings from this nested case-control study of men routinely screened for prostate cancer and who had a high prevalence of overweight and obesity do not provide evidence to support that prediagnostic obesity or factors elaborated by fat cells strongly influence prostate cancer risk or aggressiveness. However, due to the small sample population, a small or modest effect of obesity and adipokines on these outcomes cannot be excluded.

Original languageEnglish (US)
Pages (from-to)1331-1335
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume15
Issue number7
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Adipokines
Prostatic Neoplasms
Obesity
Odds Ratio
Confidence Intervals
Population
Adiponectin
Leptin
Interleukin-6
Body Mass Index
Logistic Models
Adipocytes
Case-Control Studies
Cohort Studies
Biomarkers

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Baillargeon, J., Platz, E. A., Rose, D. P., Pollock, B. H., Ankerst, D. P., Haffner, S., ... Thompson, I. M. (2006). Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiology Biomarkers and Prevention, 15(7), 1331-1335. https://doi.org/10.1158/1055-9965.EPI-06-0082

Obesity, adipokines, and prostate cancer in a prospective population-based study. / Baillargeon, Jacques; Platz, Elizabeth A.; Rose, David P.; Pollock, Brad H.; Ankerst, Donna Pauler; Haffner, Steven; Higgins, Betsy; Lokshin, Anna; Troyer, Dean; Hernandez, Javier; Lynch, Steve; Leach, Robin J.; Thompson, Ian M.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 15, No. 7, 07.2006, p. 1331-1335.

Research output: Contribution to journalArticle

Baillargeon, J, Platz, EA, Rose, DP, Pollock, BH, Ankerst, DP, Haffner, S, Higgins, B, Lokshin, A, Troyer, D, Hernandez, J, Lynch, S, Leach, RJ & Thompson, IM 2006, 'Obesity, adipokines, and prostate cancer in a prospective population-based study', Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 7, pp. 1331-1335. https://doi.org/10.1158/1055-9965.EPI-06-0082
Baillargeon, Jacques ; Platz, Elizabeth A. ; Rose, David P. ; Pollock, Brad H. ; Ankerst, Donna Pauler ; Haffner, Steven ; Higgins, Betsy ; Lokshin, Anna ; Troyer, Dean ; Hernandez, Javier ; Lynch, Steve ; Leach, Robin J. ; Thompson, Ian M. / Obesity, adipokines, and prostate cancer in a prospective population-based study. In: Cancer Epidemiology Biomarkers and Prevention. 2006 ; Vol. 15, No. 7. pp. 1331-1335.
@article{89b8b76b545242c0b8efa39f0311ebc3,
title = "Obesity, adipokines, and prostate cancer in a prospective population-based study",
abstract = "Background: The purpose of this investigation was to examine the association of obesity and the adipokines leptin, adiponectin, and interleukin-6 (IL-6) with prostate cancer risk and aggressiveness. Methods: One hundred twenty-five incident prostate cancer cases and 125 age-matched controls were sampled from among participants in the original San Antonio Center for Biomarkers of Risk of Prostate Cancer cohort study. The odds ratios (OR) of prostate cancer and high-grade disease (Gleason sum >7) associated with the WHO categories of body mass index (kg/m2) and with tertiles of serum concentrations of adiponectin, leptin, and IL-6 were estimated using multivariable conditional logistic regression models. Results: Body mass index was not associated with either incident prostate cancer [obese versus normal; OR, 0.75; 95{\%} confidence interval (95{\%} CI), 0.38-1.48; Ptrend = 0.27] or high-grade versus low-grade disease (OR, 1.17; 95{\%} CI, 0.39-3.52; P trend = 0.62). Moreover, none of the three adipokines was statistically significant associated with prostate cancer risk or high-grade disease, respectively: leptin (highest versus lowest tertile; OR, 0.77; 95{\%} CI, 0.28-1.37; Ptrend = 0.57; OR, 1.20; 95{\%} CI, 0.48-3.01; P trend = 0.85); adiponectin (OR, 0.87; 95{\%} CI, 0.46-1.65; P trend = 0.24; OR, 1.93; 95{\%} CI, 0.74-5.10; Ptrend = 0.85); IL-6 (OR, 0.84; 95{\%} CI, 0.46-1.53; Ptrend = 0.98; OR, 0.84; 95{\%} CI, 0.30-2.33; Ptrend = 0.17). Conclusions: Findings from this nested case-control study of men routinely screened for prostate cancer and who had a high prevalence of overweight and obesity do not provide evidence to support that prediagnostic obesity or factors elaborated by fat cells strongly influence prostate cancer risk or aggressiveness. However, due to the small sample population, a small or modest effect of obesity and adipokines on these outcomes cannot be excluded.",
author = "Jacques Baillargeon and Platz, {Elizabeth A.} and Rose, {David P.} and Pollock, {Brad H.} and Ankerst, {Donna Pauler} and Steven Haffner and Betsy Higgins and Anna Lokshin and Dean Troyer and Javier Hernandez and Steve Lynch and Leach, {Robin J.} and Thompson, {Ian M.}",
year = "2006",
month = "7",
doi = "10.1158/1055-9965.EPI-06-0082",
language = "English (US)",
volume = "15",
pages = "1331--1335",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Obesity, adipokines, and prostate cancer in a prospective population-based study

AU - Baillargeon, Jacques

AU - Platz, Elizabeth A.

AU - Rose, David P.

AU - Pollock, Brad H.

AU - Ankerst, Donna Pauler

AU - Haffner, Steven

AU - Higgins, Betsy

AU - Lokshin, Anna

AU - Troyer, Dean

AU - Hernandez, Javier

AU - Lynch, Steve

AU - Leach, Robin J.

AU - Thompson, Ian M.

PY - 2006/7

Y1 - 2006/7

N2 - Background: The purpose of this investigation was to examine the association of obesity and the adipokines leptin, adiponectin, and interleukin-6 (IL-6) with prostate cancer risk and aggressiveness. Methods: One hundred twenty-five incident prostate cancer cases and 125 age-matched controls were sampled from among participants in the original San Antonio Center for Biomarkers of Risk of Prostate Cancer cohort study. The odds ratios (OR) of prostate cancer and high-grade disease (Gleason sum >7) associated with the WHO categories of body mass index (kg/m2) and with tertiles of serum concentrations of adiponectin, leptin, and IL-6 were estimated using multivariable conditional logistic regression models. Results: Body mass index was not associated with either incident prostate cancer [obese versus normal; OR, 0.75; 95% confidence interval (95% CI), 0.38-1.48; Ptrend = 0.27] or high-grade versus low-grade disease (OR, 1.17; 95% CI, 0.39-3.52; P trend = 0.62). Moreover, none of the three adipokines was statistically significant associated with prostate cancer risk or high-grade disease, respectively: leptin (highest versus lowest tertile; OR, 0.77; 95% CI, 0.28-1.37; Ptrend = 0.57; OR, 1.20; 95% CI, 0.48-3.01; P trend = 0.85); adiponectin (OR, 0.87; 95% CI, 0.46-1.65; P trend = 0.24; OR, 1.93; 95% CI, 0.74-5.10; Ptrend = 0.85); IL-6 (OR, 0.84; 95% CI, 0.46-1.53; Ptrend = 0.98; OR, 0.84; 95% CI, 0.30-2.33; Ptrend = 0.17). Conclusions: Findings from this nested case-control study of men routinely screened for prostate cancer and who had a high prevalence of overweight and obesity do not provide evidence to support that prediagnostic obesity or factors elaborated by fat cells strongly influence prostate cancer risk or aggressiveness. However, due to the small sample population, a small or modest effect of obesity and adipokines on these outcomes cannot be excluded.

AB - Background: The purpose of this investigation was to examine the association of obesity and the adipokines leptin, adiponectin, and interleukin-6 (IL-6) with prostate cancer risk and aggressiveness. Methods: One hundred twenty-five incident prostate cancer cases and 125 age-matched controls were sampled from among participants in the original San Antonio Center for Biomarkers of Risk of Prostate Cancer cohort study. The odds ratios (OR) of prostate cancer and high-grade disease (Gleason sum >7) associated with the WHO categories of body mass index (kg/m2) and with tertiles of serum concentrations of adiponectin, leptin, and IL-6 were estimated using multivariable conditional logistic regression models. Results: Body mass index was not associated with either incident prostate cancer [obese versus normal; OR, 0.75; 95% confidence interval (95% CI), 0.38-1.48; Ptrend = 0.27] or high-grade versus low-grade disease (OR, 1.17; 95% CI, 0.39-3.52; P trend = 0.62). Moreover, none of the three adipokines was statistically significant associated with prostate cancer risk or high-grade disease, respectively: leptin (highest versus lowest tertile; OR, 0.77; 95% CI, 0.28-1.37; Ptrend = 0.57; OR, 1.20; 95% CI, 0.48-3.01; P trend = 0.85); adiponectin (OR, 0.87; 95% CI, 0.46-1.65; P trend = 0.24; OR, 1.93; 95% CI, 0.74-5.10; Ptrend = 0.85); IL-6 (OR, 0.84; 95% CI, 0.46-1.53; Ptrend = 0.98; OR, 0.84; 95% CI, 0.30-2.33; Ptrend = 0.17). Conclusions: Findings from this nested case-control study of men routinely screened for prostate cancer and who had a high prevalence of overweight and obesity do not provide evidence to support that prediagnostic obesity or factors elaborated by fat cells strongly influence prostate cancer risk or aggressiveness. However, due to the small sample population, a small or modest effect of obesity and adipokines on these outcomes cannot be excluded.

UR - http://www.scopus.com/inward/record.url?scp=33746437919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746437919&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-06-0082

DO - 10.1158/1055-9965.EPI-06-0082

M3 - Article

C2 - 16835332

AN - SCOPUS:33746437919

VL - 15

SP - 1331

EP - 1335

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -